NextCell Pharma AB announced that the company has signed an agreement with Linio to warehouse and distribute Tience in Sweden. The value of the agreement for the first year amounts to approximately SEK 400,000 in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles.

The product is marketed and sold by Linio to clinics and hospitals. The private stem cell bank Cellaviva, which is owned by NextCell, has been licensed from the Swedish Health Authority (IVO) to operate a tissue facility in Sweden since 2014, which is a regulatory requirement to handle this type of product. Logistics, distribution, and warehousing are core business activities for Cellaviva, and Tience is a welcome source of income that generates profit from the start, regardless of the strength of sales.

The great interest in this type of product could soon provide Cellaviva with significant revenue in variable remuneration.